It is profound that despite years of intensive therapeutic efforts, 50-60% of patients with muscle-invasive urothelial bladder cancer will have a local or distant disease recurrence within 5 years with limited further therapy options. The primary research goal of our translational working group is to promote personalized therapy for patients with muscle-invasive bladder cancer patients to improve their outcome after curative treatment approaches. Therefore, our main research focus is to perform an in-depth characterization of the tumor immune microenvironment of locally advanced and metastatic urothelial bladder cancer.